Literature DB >> 29925695

A porcine model of neurofibromatosis type 1 that mimics the human disease.

Katherine A White1, Vicki J Swier1, Jacob T Cain1, Jordan L Kohlmeyer2, David K Meyerholz3, Munir R Tanas3, Johanna Uthoff4,5, Emily Hammond4,5, Hua Li6,7, Frank A Rohret8, Adam Goeken3, Chun-Hung Chan1, Mariah R Leidinger3, Shaikamjad Umesalma9, Margaret R Wallace6,7, Rebecca D Dodd10,11, Karin Panzer12, Amy H Tang13, Benjamin W Darbro11,12, Aubin Moutal14, Song Cai14, Wennan Li14, Shreya S Bellampalli14, Rajesh Khanna14, Christopher S Rogers8, Jessica C Sieren4,5,11, Dawn E Quelle2,3,9,11, Jill M Weimer1,15.   

Abstract

Loss of the NF1 tumor suppressor gene causes the autosomal dominant condition, neurofibromatosis type 1 (NF1). Children and adults with NF1 suffer from pathologies including benign and malignant tumors to cognitive deficits, seizures, growth abnormalities, and peripheral neuropathies. NF1 encodes neurofibromin, a Ras-GTPase activating protein, and NF1 mutations result in hyperactivated Ras signaling in patients. Existing NF1 mutant mice mimic individual aspects of NF1, but none comprehensively models the disease. We describe a potentially novel Yucatan miniswine model bearing a heterozygotic mutation in NF1 (exon 42 deletion) orthologous to a mutation found in NF1 patients. NF1+/ex42del miniswine phenocopy the wide range of manifestations seen in NF1 patients, including café au lait spots, neurofibromas, axillary freckling, and neurological defects in learning and memory. Molecular analyses verified reduced neurofibromin expression in swine NF1+/ex42del fibroblasts, as well as hyperactivation of Ras, as measured by increased expression of its downstream effectors, phosphorylated ERK1/2, SIAH, and the checkpoint regulators p53 and p21. Consistent with altered pain signaling in NF1, dysregulation of calcium and sodium channels was observed in dorsal root ganglia expressing mutant NF1. Thus, these NF1+/ex42del miniswine recapitulate the disease and provide a unique, much-needed tool to advance the study and treatment of NF1.

Entities:  

Keywords:  Neuroimaging; Neurological disorders; Neuroscience; Oncology

Mesh:

Substances:

Year:  2018        PMID: 29925695      PMCID: PMC6124439          DOI: 10.1172/jci.insight.120402

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  79 in total

Review 1.  Type 1 neurofibromatosis and the pediatric patient.

Authors:  V M Riccardi
Journal:  Curr Probl Pediatr       Date:  1992-02

Review 2.  Clinical manifestations and management of neurofibromatosis type 1.

Authors:  James H Tonsgard
Journal:  Semin Pediatr Neurol       Date:  2006-03       Impact factor: 1.636

3.  Neurofibromin regulates corticostriatal inhibitory networks during working memory performance.

Authors:  Carrie Shilyansky; Katherine H Karlsgodt; Damian M Cummings; Kyriaki Sidiropoulou; Molly Hardt; Alex S James; Dan Ehninger; Carrie E Bearden; Panayiota Poirazi; J David Jentsch; Tyrone D Cannon; Michael S Levine; Alcino J Silva
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-12       Impact factor: 11.205

4.  Treatment of ADHD in neurofibromatosis type 1.

Authors:  Victor-F Mautner; Lan Kluwe; Sarang D Thakker; Robert A Leark
Journal:  Dev Med Child Neurol       Date:  2002-03       Impact factor: 5.449

5.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

Review 6.  The pathoetiology of neurofibromatosis 1.

Authors:  Eeva-Mari Jouhilahti; Sirkku Peltonen; Anthony M Heape; Juha Peltonen
Journal:  Am J Pathol       Date:  2011-03-31       Impact factor: 4.307

7.  Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.

Authors:  Eva Dombi; Andrea Baldwin; Leigh J Marcus; Michael J Fisher; Brian Weiss; AeRang Kim; Patricia Whitcomb; Staci Martin; Lindsey E Aschbacher-Smith; Tilat A Rizvi; Jianqiang Wu; Rachel Ershler; Pamela Wolters; Janet Therrien; John Glod; Jean B Belasco; Elizabeth Schorry; Alessandra Brofferio; Amy J Starosta; Andrea Gillespie; Austin L Doyle; Nancy Ratner; Brigitte C Widemann
Journal:  N Engl J Med       Date:  2016-12-29       Impact factor: 91.245

Review 8.  The neurofibromatosis type 1 gene and its protein product, neurofibromin.

Authors:  D H Gutmann; F S Collins
Journal:  Neuron       Date:  1993-03       Impact factor: 17.173

9.  Effect of disrupting seven-in-absentia homolog 2 function on lung cancer cell growth.

Authors:  Atique U Ahmed; Rebecca L Schmidt; Cheol Hong Park; Nanette R Reed; Shayla E Hesse; Charles F Thomas; Julian R Molina; Claude Deschamps; Ping Yang; Marie C Aubry; Amy H Tang
Journal:  J Natl Cancer Inst       Date:  2008-11-11       Impact factor: 13.506

10.  Mounier-Kuhn syndrome: a case of tracheal smooth muscle remodeling.

Authors:  Daniel P Cook; Ryan J Adam; Mahmoud H Abou Alaiwa; Michael Eberlein; Julia A Klesney-Tait; Kalpaj R Parekh; David K Meyerholz; David A Stoltz
Journal:  Clin Case Rep       Date:  2016-12-29
View more
  15 in total

Review 1.  An update on the central nervous system manifestations of neurofibromatosis type 1.

Authors:  J Stephen Nix; Jaishri Blakeley; Fausto J Rodriguez
Journal:  Acta Neuropathol       Date:  2019-04-08       Impact factor: 17.088

2.  Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.

Authors:  J Uthoff; F A De Stefano; K Panzer; B W Darbro; T S Sato; R Khanna; D E Quelle; D K Meyerholz; J Weimer; J C Sieren
Journal:  J Neuroradiol       Date:  2018-06-27       Impact factor: 3.447

Review 3.  Towards a neurobiological understanding of pain in neurofibromatosis type 1: mechanisms and implications for treatment.

Authors:  Shreya S Bellampalli; Rajesh Khanna
Journal:  Pain       Date:  2019-05       Impact factor: 6.961

4.  RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors.

Authors:  Jordan L Kohlmeyer; Courtney A Kaemmer; Casey Pulliam; Chandra K Maharjan; Allison Moreno Samayoa; Heather J Major; Kendall E Cornick; Vickie Knepper-Adrian; Rajesh Khanna; Jessica C Sieren; Mariah R Leidinger; David K Meyerholz; K D Zamba; Jill M Weimer; Rebecca D Dodd; Benjamin W Darbro; Munir R Tanas; Dawn E Quelle
Journal:  Clin Cancer Res       Date:  2020-02-21       Impact factor: 12.531

Review 5.  Therapeutic landscape for Batten disease: current treatments and future prospects.

Authors:  Tyler B Johnson; Jacob T Cain; Katherine A White; Denia Ramirez-Montealegre; David A Pearce; Jill M Weimer
Journal:  Nat Rev Neurol       Date:  2019-03       Impact factor: 42.937

6.  Assessment of nociception and related quality-of-life measures in a porcine model of neurofibromatosis type 1.

Authors:  Rajesh Khanna; Aubin Moutal; Katherine A White; Aude Chefdeville; Pedro Negrao de Assis; Song Cai; Vicki J Swier; Shreya S Bellampalli; Marissa D Giunta; Benjamin W Darbro; Dawn E Quelle; Jessica C Sieren; Margaret R Wallace; Christopher S Rogers; David K Meyerholz; Jill M Weimer
Journal:  Pain       Date:  2019-11       Impact factor: 7.926

Review 7.  Spontaneous and Engineered Large Animal Models of Neurofibromatosis Type 1.

Authors:  Sara H Osum; Adrienne L Watson; David A Largaespada
Journal:  Int J Mol Sci       Date:  2021-02-16       Impact factor: 6.208

Review 8.  Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis.

Authors:  Ryota Tamura
Journal:  Int J Mol Sci       Date:  2021-05-29       Impact factor: 5.923

9.  Validating indicators of CNS disorders in a swine model of neurological disease.

Authors:  Vicki J Swier; Katherine A White; David K Meyerholz; Aude Chefdeville; Rajesh Khanna; Jessica C Sieren; Dawn E Quelle; Jill M Weimer
Journal:  PLoS One       Date:  2020-02-19       Impact factor: 3.752

Review 10.  Neurofibromin Structure, Functions and Regulation.

Authors:  Mohammed Bergoug; Michel Doudeau; Fabienne Godin; Christine Mosrin; Béatrice Vallée; Hélène Bénédetti
Journal:  Cells       Date:  2020-10-27       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.